EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival

Gil-Ran Kim iD, Kyung-Ho Nam iD, Je-Min Choi iD

Clinical Transplantation and Research · 31.12.2024 · 38 (4) · 326-340

DOI: 10.4285/ctr.24.0057 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Transplantation and Research, online erschienen am 18.12.2024. Verfasst von Gil-Ran Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Korea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcineurin inhibitors (CNIs) have been a cornerstone in solid organ transplantation for many years; however, their prolonged use is linked to significant adverse effects, most notably nephrotoxicity. Belatacept, a modified version of cytotoxic T lymphocyte antigen-4 immunoglobulin with increased binding affinity for its ligand, has emerged as a viable alternative to traditional CNIs due to its lower toxicity profile. Despite these benefits, belatacept is associated with a higher rate of acute rejection, which presents a challenge for long-term graft survival. This review reevaluates the limitations of belatacept in achieving long-term acceptance of transplants and highlights the importance of regulatory T (Treg) cells in maintaining immune tolerance and preventing graft rejection. Additionally, it discusses the potential benefits of combining therapies that boost Treg cells with belatacept to increase the effectiveness of immunosuppression and improve graft outcomes.

Schlagwörter

Stichwörter der Autor:innen

AbataceptRegulatory T cellsTransplantation

Autor:innen und Institutionen

  • Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Korea.
  • Research Institute for Natural Sciences, Hanyang University, Seoul, Korea.
  • Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
  • Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul, Korea.

ORCID-Profile: Gil-Ran Kim, Kyung-Ho Nam, Je-Min Choi

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Kim, G. R., Nam, K. H., & Choi, J. M. (2024). Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival. Clinical Transplantation and Research, 38(4), 326-340. https://doi.org/10.4285/ctr.24.0057

Vancouver

Kim GR, Nam KH, Choi JM. Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival. Clinical Transplantation and Research. 2024;38(4):326-340. doi:10.4285/ctr.24.0057

BibTeX
@article{Kim2024,
  author = {Kim, Gil-Ran and Nam, Kyung-Ho and Choi, Je-Min},
  title = {Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival},
  journal = {Clinical Transplantation and Research},
  year = {2024},
  volume = {38},
  number = {4},
  pages = {326--340},
  doi = {10.4285/ctr.24.0057}
}
Kostenlos starten →